ArticleeLife2020
Re-expression of SMARCA4/BRG1 in small cell carcinoma of ovary, hypercalcemic type (SCCOHT) promotes an epithelial-like gene signature through an AP-1-dependent mechanism.
Open access · goldAbstract read
In one paragraph
Article in eLife, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 49 citations in OpenAlex.
- SMARCA4 loss reprograms p300 chromatin occupancy to subvert p53-mediated transcriptional repression in ovarian small cell carcinoma.Nature communications · 2026Article
- Clinicopathological and molecular characteristics of small cell carcinoma of the ovary, hypercalcemic type: three case reports.Discover oncology · 2026Article
- SMARCA4/2 loss reduces BCL-xL expression and confers a druggable MCL1 dependency in cancer.NPJ precision oncology · 2026Article
- Chromatin Accessibility in Cancer: Biological Functions, Mechanisms, Therapeutic Potential, and Future Directions.MedComm · 2026Review
- SMARCA4 deficiency in glioblastoma: Mitochondrial transfer from MSCs and the clinical dilemma in targeting the tumor microenvironment.Neoplasia (New York, N.Y.) · 2026Article
- SWI/SNF complexes govern ontology-specific transcription factor function in MYC-subtype atypical teratoid rhabdoid tumor.Neuro-oncology · 2025Article
- BRG1 Loss Is Frequent in Lung Cancer and Transforms Lung Epithelial Cells via Transcriptional and Epigenetic Reprograming.Cancers · 2025Article
- Precise modulation of BRG1 levels reveals features of mSWI/SNF dosage sensitivity.Nature genetics · 2025Article
- Altered cofactor recruitment and nucleosome dynamics underlie bisphenol A's impact on ERα-mediated transcriptional bursting.iScience · 2025Article
- Loss of SMARCA4 Leads to Intron Retention and Generation of Tumor-Associated Antigens in Small Cell Carcinoma of the Ovary, Hypercalcemic Type.Cancer research · 2025Article
- MYC Regulates a DNA Repair Gene Expression Program in Small Cell Carcinoma of the Ovary, Hypercalcemic Type.Cancers · 2025Article
- Pioneering new enhancers by GATA3: role of facilitating transcription factors and chromatin remodeling.Nucleic acids research · 2025Article
- SMARCA4 regulates the NK-mediated killing of senescent cells.Science advances · 2025Article
- Efficacy of glutathione inhibitor eprenetapopt against the vulnerability of glutathione metabolism in SMARCA4-, SMARCB1- and PBRM1-deficient cancer cells.Scientific reports · 2024Article
- Article
- Review
- Single-Cell Evolutionary Analysis Reveals Drivers of Plasticity and Mediators of Chemoresistance in Small Cell Lung Cancer.Molecular cancer research : MCR · 2023Article
- The CUT&RUN suspect list of problematic regions of the genome.Genome biology · 2023Article
- Alanine supplementation exploits glutamine dependency induced by SMARCA4/2-loss.Nature communications · 2023Article
- BRG1 HSA domain interactions with BCL7 proteins are critical for remodeling and gene expression.Life science alliance · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 7 institutions in 3 countries.
Krystal Ann OrlandoDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, United States.ORCID 0000-0001-5790-8843
Amber K DouglasLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, United States.
Aierken AbuduDepartment of Microbiology and Molecular Genetics, Michigan State University, East Lansing, United States.
Yemin WangDepartment of Pathology and Laboratory Medicine, University of British Columbia and Department of Molecular Oncology, British Columbia Cancer Research Institute, Vancouver, Canada.
Basile Tessier-CloutierDepartment of Pathology and Laboratory Medicine, University of British Columbia and Department of Molecular Oncology, British Columbia Cancer Research Institute, Vancouver, Canada.
Weiping SuDivision of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, United States.
Alec PetersDivision of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, United States.
Larry S ShermanDivision of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, United States.
Rayvon MooreLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, United States.
Vinh NguyenLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, United States.
Gian Luca NegriMichael Smith Genome Science Centre, British Columbia Cancer Research Institute, Vancouver, Canada.ORCID 0000-0001-7722-8888
Shane ColborneMichael Smith Genome Science Centre, British Columbia Cancer Research Institute, Vancouver, Canada.
Gregg B MorinMichael Smith Genome Science Centre, British Columbia Cancer Research Institute, Vancouver, Canada.
Friedrich KommossSynlab MVZ Pathologie, Mannheim, Germany.
Jessica D LangDivision of Integrated Cancer Genomics, Translational Genomics Research Institute (TGen), Phoenix, United States.ORCID 0000-0001-9700-4785
William Pd HendricksDivision of Integrated Cancer Genomics, Translational Genomics Research Institute (TGen), Phoenix, United States.
Elizabeth A RaupachDivision of Integrated Cancer Genomics, Translational Genomics Research Institute (TGen), Phoenix, United States.
Patrick PirrotteCollaborative Center for Translational Mass Spectrometry, Translational Genomics Research Institute (TGen), Phoenix, United States.
David G HuntsmanDepartment of Pathology and Laboratory Medicine, University of British Columbia and Department of Molecular Oncology, British Columbia Cancer Research Institute, Vancouver, Canada.
Jeffrey M TrentDivision of Integrated Cancer Genomics, Translational Genomics Research Institute (TGen), Phoenix, United States.
Joel S ParkerLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, United States.
Jesse R RaabLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, United States.ORCID 0000-0001-6387-8994
Bernard E WeissmanDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, United States.ORCID 0000-0002-1827-2309
University of North Carolina at Chapel Hill · USTranslational Genomics Research Institute · USUniversity of British Columbia · CAOregon National Primate Research Center · USCanada's Michael Smith Genome Sciences Centre · CAMichigan State University · USSynlab (Germany) · DE
Funding
Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9MVirology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5MTransgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3MTOXICOLOGYT32ES007126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ILONA JASPERS, Bernard E. Weissman · 1985 to 2026
$13.0MThe Tumor Suppressor Role of SMARCA4 in SCCOHTR01CA195670 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HUNTSMAN, DAVID, TRENT, JEFFREY M. · 2015 to 2019
$3.7MDepartment of Defense W81XWH-19-1-0423NCI NIH HHS P30 CA016086NCI NIH HHS P30 CA033572NCI NIH HHS R01 CA195670NIEHS NIH HHS T32 ES007126NIH HHS P51 OD 011092NIH HHS P51 OD011092
Abstract
Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare and aggressive form of ovarian cancer. SCCOHT tumors have inactivating mutations in
Indexed as
Biomarkers, TumorCarcinoma, Small CellCell Line, TumorCell Transformation, NeoplasticDNA HelicasesFemaleHumansHypercalcemiaMutationNuclear ProteinsOvarian NeoplasmsOvaryTranscription Factor AP-1Transcription FactorsBiomarkers, TumorDNA HelicasesNuclear ProteinsSMARCA4 protein, humanTranscription Factor AP-1Transcription FactorsAP-1BRG1cancer biologyEpithelialhumanmulti-omicsSCCOHTSWI/SNF
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.